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Abstract
Different vaccine approaches cope with HIV-1 diversity, ranging from centralized
1–4 to variability-encompassing
5–7 antigens.
For all these strategies, a concern remains: how does HIV-1 diversity impact epitope recognition by the immune system? We
studied the relationship between HIV-1 diversity and CD8
+ T Lymphocytes (CTL) targeting of HIV-1 subtype B Nef using 944
peptides (10-mers overlapping by nine amino acids (AA)) that corresponded to consensus peptides and their most common
variants in the HIV-1-B virus population. IFN-c ELISpot assays were performed using freshly isolated PBMC from 26 HIV-1-
infected persons. Three hundred and fifty peptides elicited a response in at least one individual. Individuals targeted a
median of 7 discrete regions. Overall, 33% of responses were directed against viral variants but not elicited against
consensus-based test peptides. However, there was no significant relationship between the frequency of a 10-mer in the
viral population and either its frequency of recognition (Spearman’s correlation coefficient r=0.24) or the magnitude of the
responses (r=0.16). We found that peptides with a single mutation compared to the consensus were likely to be
recognized (especially if the change was conservative) and to elicit responses of similar magnitude as the consensus
peptide. Our results indicate that cross-reactivity between rare and frequent variants is likely to play a role in the expansion
of CTL responses, and that maximizing antigenic diversity in a vaccine may increase the breadth and depth of CTL
responses. However, since there are few obvious preferred pathways to virologic escape, the diversity that may be required
to block all potential escape pathways may be too large for a realistic vaccine to accommodate. Furthermore, since peptides
were not recognized based on their frequency in the population, it remains unclear by which mechanisms variability-
inclusive antigens (i.e., constructs enriched with frequent variants) expand CTL recognition.
Citation: Rolland M, Frahm N, Nickle DC, Jojic N, Deng W, et al. (2011) Increased Breadth and Depth of Cytotoxic T Lymphocytes Responses against HIV-1-B Nef
by Inclusion of Epitope Variant Sequences. PLoS ONE 6(3): e17969. doi:10.1371/journal.pone.0017969
Editor: Vladimir Brusic, Dana-Farber Cancer Institute, United States of America
Received October 19, 2010; Accepted February 21, 2011; Published March 28, 2011
Copyright:  2011 Rolland et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an unrestricted gift from Microsoft Research, the Bill and Melinda Gates Foundation (43437) and by grants to MR from
amfAR (Mathilde Krim Fellowship - 107005-43-RFNT), the Computational Biology Core of the University of Washington Centers for AIDS Research and STD
(National Institutes of Health AI27757), and a grant to JIM from the University of Washington Center for AIDS Research (P30 AI27757)(bioinformatics core). These
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. DEH is an employee of Microsoft Research
and MR is currently employed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) (this study was completed prior to MR’s
employment at HJF).
Competing Interests: David E. Heckerman is an employee of Microsoft Research. This does not alter the authors’ adherence to all the PLoS ONE policies on
sharing data and materials, as detailed online in the guide for authors.
* E-mail: mrolland@hivresearch.org
. These authors contributed equally to this work.
¤a Current address: Military HIV Research Program, Henry M. Jackson Foundation, Rockville, Maryland, United States of America
¤b Current address: Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
Introduction
Despite setbacks in the development of CTL-based HIV
vaccines [1], it seems likely that this approach will remain a
crucial component of future vaccine strategies given amassed
evidence on the critical role of the cell-mediated host immune
response against HIV-1 [2,3,4,5,6]. Certain characteristics of CTL
responses attest to their importance, e.g., the emergence of CD8+
T lymphocytes has been temporally linked with the decline in
viremia in early infection [2,4]; some MHC class I alleles are
associated with HIV-1 disease outcomes [7,8,9]; CTL targeting of
specific proteins/epitopes, such as within Gag, has been associated
with control of viral load [10,11]. While it is apparent that
antiviral CTL immune responses vary in their ability to contain
HIV-1 replication, there is still no precise definition of mechanisms
of protection against HIV-1 disease progression and, as such, no
rational path toward a successful CTL-based vaccine.
Post-Step trial suggestions emphasize the potential benefit of
strategies that would improve T cell breadth [1]. Such vaccine
strategies have been proposed, e.g., for HIV-1 the mosaic [12] and
COT+ [13] approaches, or the epitome for Hepatitis C [14].
These vaccine designs compress HIV-1 diversity to maximize the
coverage of circulating strains: the proposed inserts include the
most common variants of HIV-1, thereby infecting strains will be
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antigen. The rationale is that the efficacy of variability-inclusive
vaccine will be maximized because peptides identical between the
antigen and the breakthrough strain would be recognized by T
cells primed by the vaccine upon breakthrough infection. Indeed,
two recent studies demonstrated that mosaic HIV-1 vaccines
increased the breadth and depth of cellular immune responses in
Rhesus monkeys [15,16], especially in the case of bivalent mosaic
HIV-1-B Gag, Pol and Env antigens expressed by recombinant
adenovirus serotype 26 vectors [15].
Although it is agreed that HIV-1’s extensive variability is a
major challenge for a successful vaccine strategy, which must
control extremely diverse viral strains, the impact of HIV-1
diversity on CTL targeting remains poorly understood. Our
knowledge of HIV-1 diversity and CTL recognition is mostly
derived from whole genome mapping studies of ELISpot responses
using consensus peptides and small studies of specific epitopes in
HIV-1-infected individuals with longitudinal follow-up, particu-
larly in the context of CTL escape.
We sought to formally analyze the effect of HIV-1 diversity on
CTL targeting of Nef, as it comprises both conserved and variable
segments and is often targeted both during acute/early and
chronic infection: several Nef peptides were recognized by more
than 40% of individuals in large cohorts of Americans or South-
Africans infected with HIV-1 subtype B and C, respectively
[11,17]. Based on accumulated sequence data from the Los
Alamos HIV Database (HIVDB) for HIV-1 subtype B Nef, we
synthesized peptides corresponding to the consensus sequence and
several naturally occurring mutants. The peptide set also included
all peptides derived from a 3-gene-length Nef COT+ antigen [13]:
with the COT+ strategy, the initial gene-length corresponds to a
Center-Of-Tree (COT) sequence [18] then common 9-mer Nef
variants are appended based on their frequency among circulating
viruses until the pre-set length of the construct is reached. In total,
the peptide library contained 944 Nef peptides which were tested
for immune recognition in HIV-1 infected individuals in order to
assess the impact of HIV-1 diversity on CTL recognition and to
assess the improvement in viral epitope recognition afforded by a
theoretical variability-inclusive vaccine candidate.
Here, we identified novel HIV-1 Nef epitopes and showed that
there is no general relationship between the frequency of an HIV-
1 peptide among circulating sequences and its frequency of
recognition in the cohort. These findings challenge immunogen
designs that are based on a ‘‘frequency-only’’ criterion for variant
inclusion and warrant further studies into the determinants of
CTL variant recognition in HIV-1.
Materials and Methods
Study Subjects
Subjects with chronic HIV infection were recruited at three
hospitals in the Boston area. All human subject protocols were
approved by the Partners Human Research Committee, and all
subjects provided written informed consent prior to enrollment.
HIV-1 subtype B Nef Peptides
Nine hundred and forty four 10-mer peptides overlapping by 9
AA were synthesized and used in the present study. These
sequences cover the distribution of HIV-1 B viral sequences based
on a previously described [13] dataset of 169 sequences available
in the HIVDB. These variants included: i) peptides corresponding
to the full-length consensus subtype B 2004 Nef; ii) peptides
corresponding to the full-length COT subtype B [18]; iii) 10-mers
corresponding to three natural HIV-1 B sequences optimized for
combined sequence coverage (‘3-Best’) (GenBank ids: U34603,
AF004394, DQ121883), and iv) 10-mers covering the 3-gene-
length Nef COT+ HIV-1 B antigen (the first gene length
corresponds to COT, two additional gene lengths correspond to
high-frequency peptides; COT+ peptides also include five artificial
10-mers that are a sequel of the COT+ design strategy) [13]. We
chose 10-AA-long peptides to increase sensitivity for in vitro IFN-c
ELISpot assays and to better discriminate responses to multiple
partly overlapping peptides from individual discrete specificities.
Variability metrics
Shannon entropy. Shannon entropy was used to score the
variability at each position of an alignment of HIV-1 circulating
sequences [19]. Five hundred and fourteen independent Nef HIV-
1 subtype B sequences were gathered from the HIVDB. Shannon
entropy values were determined at each site in the AA-alignment
and average Shannon entropy values were calculated for each
peptide over the corresponding positions.
Population frequency. We derived all unique 10-mers in the
514-sequence-dataset and defined their population frequency, i.e.,
the percentage of sequences with the precise 10-mer sequence
present in the dataset of 514 Nef sequences.
IFN-c ELISpot assays
IFN-c ELISpot assays were performed on freshly isolated
peripheral blood mononuclear cells (PBMC) from 26 individuals.
All peptides were tested in separate wells of the Elispot plates. Due
to the large number of peptides tested, not all blood draws yielded
sufficient PBMC to test at 100,000 cells/well, therefore assays were
run with 74,000 to 100,000 cells/well (median 100,000 cells/well).
To be scored as positive, a response had to be greater than: a) four
times the mean background, b) the mean background plus three
standard deviations, c) five spots per well and d) 55 spot-forming
cells per million (SFC/M).
Cross-reactivity model
The HIV-1-B Nef peptides that were reactive in the ELISpot
assays were compared by testing k-mers (with k=8, 9, 10 AA) that
had the same HIV-1 HXB2 strain coordinates; in brief, a
consensus k-mer was compared to its variant k-mer(s), with k
being of the same length for the consensus and variant to avoid the
creation of gaps when aligning the 2 k-mers. Pairs of peptides were
tested when the database frequency of one of the peptides was at
least ten-fold greater than that of the other k-mer. For each given
10-mer peptide pair, cross-reactivity was also assessed for the two
pairs of 9-mers and three pairs of 8-mers nested in the 10-mer. We
computed a cross-reactivity fraction corresponding to the number
of individuals who recognized the less frequent peptide divided by
the number of individuals who recognized the more common one.
AA substitutions were characterized as being conservative, semi-
conservative and non-conservative based on the Dayhoff PAM250
matrix [20].
Results
Design of 944 peptides in Nef HIV-1 Subtype B
Most Nef peptides are unique or very rare at the population
level. We dissected 514 Nef HIV-1 B sequences into overlapping
10-mers and found 19,860 unique 10-mers: a small fraction of
relatively frequent peptides and a long tail of rare 10-mers. More
than 2/3 of all of these peptides were engendered by private
mutations, i.e., 13,574 peptides were found only once in this
dataset (Figure S1). For the experimental assays, 944 10-mers
overlapping by 9 AA had been designed to cover a fraction of the
Nef Recognition by CTL
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based on a previously described dataset of 169 sequences [13].
Five synthetic peptides were integrated in the set that were
unnatural junctional peptide sequels of the COT+ design,
however, they were not recognized in our cohort. When all
peptides were mapped along the Nef protein based on their
corresponding start positions in the HXB2 reference sequence,
consensus peptides covered the full length of Nef and a median of
four additional peptides represented the variants found for each
consensus peptide, with up to eight variants for the three most
diverse segments of Nef (Figure S2).
Identification of novel HIV-1 Subtype B Nef epitopes
The 944 Nef peptides were tested by IFN-c ELISpot assays
using fresh PBMC from 26 HIV-1 infected persons (Table S1).
Viral loads did not influence the recognition by IFN-c ELISpot
assays: among untreated subjects, there was no significant
relationship between viral load and either the number of ELISpot
responses (r
2=0.05; p=0.001) or the number of epitopes
recognized per individual (r
2=0.04; p=0.001).
While 944 peptides were tested by IFN-c ELISpot assays, only
350 elicited a response in at least 1 individual (Figure 1).
Considering the 38 known epitopes reported in the HIVDB (as
of August 31, 2009), 34 epitopes were recognized in our cohort at
least once and not necessarily in the context of the originally
described HLA allele (for 10 epitopes, recognition occurred
exclusively through alleles different from the originally described
ones). Considering that three of the not-targeted epitopes were 11-
mers whose recognition could not be effectively tested with our 10-
mer peptide library, the only previously described epitope that was
not recognized in our cohort was the B*4001/B50-restricted
epitope LEKHGAITS (Nef 37–45), although 3 individuals
presented the HLA allele B40 (only 2-digit HLA data was
available for individuals in our study).
On an individual peptide basis, the median number of ELISpot
responses per subject was 21 (interquartile range (IQR) 14–41; range
1–123). Due to the multiplicity of peptide variants tested, several
responses can be scored for the same 10-AA segment. Additionally,
due to the 1AA-offset between the peptides, the same epitope can be
found in a suite of immediately adjacent overlapping 10-mers: for
example, an 8-AA-long epitope is present in three consecutive 10-
mers. In order to count only the ELISpot responses that were
reflective of an independent CTL specificity, we scored only one
response per 10-AA segment, and, if we found two or three responses
to consecutive 10-mers, we scored them as one independent response
(four consecutive responses were counted as two independent
responses). Hence, the median number of independent epitopes
recognized per individual was seven (IQR 4–13; range 1–32).
Benefit of a coverage-optimized peptide set
To assess whether using coverage-optimized HIV-1 subtype B
vaccine inserts would engender broader and deeper CTL responses
in individuals, peptides covering three potential vaccine insert
strategies were compared: COT+, ‘3-Best’ and consensus. A three-
genelengthCOT+correspondedto561peptidesinourtestset.The
‘3-Best’ natural HIV-1 Nef strains, which were selected from the
HIVDB to afford the highest coverage of HIV-1 variability [13],
corresponded to 522 peptides. The Nef HIV-1 subtype B 2004
consensus and COT sequences corresponded to 197 peptides.
When we evaluated the number of CTL responses correspond-
ing to the 3 different Nef vaccine strategies in our cohort, we found
that more peptides matching the 3-gene-length COT+ were
targeted than peptides contained in the other strategies:
nCOT+=221, n‘3-best’=200, nCON04=95, nCOT=96. However,
the percentage of COT+ or ‘3-best’ peptides recognized was
similar (39 and 38%, respectively) while the fraction of HIV-1-B
2004 consensus or COT peptides recognized was, as expected,
higher 248 and 49% of the set, respectively. Thus, if a single
protein length peptide set is used, consensus or COT peptides are
optimal for detecting responses, yet the breadth of T cell responses
is extended with the use of coverage-optimized peptides.
Increased ELISpot recognition using epitope variants
albeit with diminishing returns
We analyzedhoweach 10-mer segment ofHXB2wasrecognized
to evaluate whether recognition was due to the consensus peptide,
one or more variant peptide(s) or a combination of consensus and
variants. We rank-ordered peptides based on their frequency in the
database calling ‘variant 1’ the peptides corresponding to the most
common epitopic variant (after the consensus) found in circulating
sequences, ‘variant 2’ corresponds to the second most frequent
peptides, and so on. Figure 2 represents whether and how each of
the 203 10-AA stretches covering HXB2 was recognized. One
hundred and thirty seven segments were recognized, while 66
segments were not recognized in our cohort despite the use of
multiple variants. Figure 2A highlights two highly immunogenic
regions (centered around positions 80 and 130) that elicited
responses to both consensus and variant peptides. Consensus
peptides were more often recognized than variant peptides: 91 of
203 consensus peptides or 45% were recognized (Table 1). The
percentage of recognition dropped with the frequency of the
variants in the circulating population: to 41% for ‘variant 1’
peptides and to 26% for ‘variant 4’ peptides. The recognition of
‘variants 5, 6, 7’ or ‘variants absent in the database’ (i.e., none of the
514 sequences in the dataset included these variants) did not appear
to correlate with their frequency in the population: none of the
variant 7 peptides were recognized, while 16 of the 43 (37%) variant
peptides absent in circulating sequences were recognized.
To better characterize the coverage enhancement afforded by
inclusion of variant peptides, we scored responses to a 10-mer only
once for each individual, i.e., if an individual responded to the
consensus we did not count responses to the other variants tested.
Figure 2B reveals the sparsity of the reactivity afforded by some
variants, underlining that variant peptides do not elicit the same
degree of recognition in the population as consensus peptides.
Table 1 shows that although 41% of variant 1 peptides were
recognized, only 25% of these peptides elicited responses in
individuals who did not recognize the consensus. With the decrease
in frequency of the variants, there was a diminishing number of new
responses observed. Twenty-nine percent of variants 3 and 26% of
variant 4 peptides were recognized, allowing the detection of
responses in 9 and 11% more individuals, respectively (who had not
recognized the consensus or more frequent variants).
In summary, each additional variant level tested yielded smaller
increases in the overall spectrum of recognition. Figure 3 shows the
proportion of responses to the 203 segments (n=137) that were
identified by recognition of consensus (n=91) or variant (n=46)
peptides. Of the variant peptide responses, 18 were elicited by
‘variants 1’, 12 more responses were detected using the second
most common variants, while identification of the last 16 responses
required seven more levels of variation.
Similar magnitudes of ELISpot responses against
consensus or variant peptides
We compared the average magnitude of responses toward the
consensus and variant peptides. Ninety-one consensus peptides
were recognized with an average magnitude of 292 SFC/M
Nef Recognition by CTL
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nized with an average magnitude of 243 SFC/M (median=170
SFC/M). Hence, the consensus and variant epitopes elicited
responses of similar magnitudes (p=0.15) (Figure S3).
Next, we analyzed the magnitude of responses for pairs of
consensus plus variant peptides, i.e., the average magnitude found
for the consensus peptide was compared to the average magnitude
elicited by the different variant peptides beginning at the same
position (irrespective of whether the individual was able to elicit
responses against both consensus and variant forms). There were
73 paired sets of consensus/variant(s) that were recognized in the
cohort. The average magnitude elicited by the consensus (318
SFC/M) or the variant peptides (261 SFC/M) were not
significantly different: p=0.80 (Figure 4).
Last, we analyzed the magnitude of responses on an individual
basis, focusing on individuals who mounted responses toward both
the consensus and one or more of the variant peptides. Of the 91
peptides that were recognized using consensus peptides, variants of
44 of these were recognized by at least one individual (and up to
11 individuals). There was no significant difference in the
magnitude of the responses elicited for the consensus or for a
variant (p=0.70).
Figure 1. Distribution of reactive 10-mers and known epitopes in Nef. The number of 10-mers that were tested are represented as gray bars.
Black bars correspond to the 10-mers that were recognized at least by one individual in our cohort. Red bars represent known epitopes that had
previously been reported in the HIVDB. Each bar is placed at the start position of each 10-mer based on their HXB2 coordinates.
doi:10.1371/journal.pone.0017969.g001
Figure 2. Distribution of reactive consensus and variant 10-mer peptides. Colored blocks correspond to the 10-mers that were recognized,
while the 10-mers that were tested are outlined in black. Recognition of peptides is figured using a gradient of colors: consensus peptides are figured
in burgundy and variant peptides follow a gradient from the most conserved (in orange) to the most rare (in purple), while peptides not found in a
database of 514 sequences are in black. Each block represents the start position of the 10-mers based on their HXB2 coordinates. Panel A shows all
the peptides recognized, panel B represents for each individual only the most frequent peptide recognized at each position (i.e., if an individual
recognized the consensus peptide and variants 1 and 4, only the recognition through the consensus is figured).
doi:10.1371/journal.pone.0017969.g002
Nef Recognition by CTL
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17969Peptides that matched the subjects’ HIV-1 sequences
elicited responses of higher magnitude
We compared the sequence of the peptides recognized by
ELISpot to nef gene sequences from the infected individual, which
were available for five individuals. When the subject’s sequence
matched the peptide sequence, the ELISpot response had a higher
magnitude than when there was a mismatch between the peptide
sequences and the individual’s virus (Figure 5). There was a trend
toward a decrease in the magnitude of responses with an increase
of peptide/virus mismatches. The average magnitude of ELISpot
Table 1. ELISpot recognition of consensus and variant peptides.
Counting all responses
Cons. Var. 1 Var. 2 Var. 3 Var. 4 Var. 5 Var. 6 Var. 7 Absent
Peptides recognized 91 81 65 40 24 14 6 0 16
Peptides not recognized 112 115 110 99 68 28 10 4 43
Peptides tested 203 196 175 139 92 42 16 4 59
% peptides recognized 44.83 41.33 37.14 28.78 26.09 33.33 37.50 0.00 27.12
Counting responses to the consensus and additional responses afforded by the addition of variants
Cons. Var. 1 Var. 2 Var. 3 Var. 4 Var. 5 Var. 6 Var. 7 Absent
Peptides recognized 91 50 33 12 10 5 1 0 10
Peptides not recognized 112 146 142 127 82 37 15 4 49
Peptides tested 203 196 175 139 92 42 16 4 59
% peptides recognized 44.83 25.51 18.86 8.63 10.87 11.90 6.25 0.00 16.95
doi:10.1371/journal.pone.0017969.t001
Figure 3. Distribution of responses between consensus and
variant 10-mers. The pie chart represents the 137 HIV-1 segments
that were recognized in our cohort and the proportion of these that
were recognized through the consensus 10-mers or through any of the
variant peptides.
doi:10.1371/journal.pone.0017969.g003
Figure 4. Magnitude of IFN-c ELISpot responses toward
consensus and variant for paired sets of peptides. Responses
of decreasing magnitude between the consensus and variant peptide
are figured in blue, responses of increasing magnitude are figured in
red.
doi:10.1371/journal.pone.0017969.g004
Nef Recognition by CTL
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matched or had one mutation with the individual’s sequences
(p=0.413), whereas the magnitude of the response was signif-
icantly lower when there were two (p=0.002) or three (p=0.039)
mismatches.
Lack of relationship between HIV-1-B Nef sequence
diversity and CTL targeting
We next examined the relationship between the ELISpot
recognition and the database variability of the HIV-1 segments
that were recognized. We calculated the average Shannon
Entropy for each 10-AA segment over the Nef protein based on
an alignment of 514 known, independent sequences. The HIV-1
segments that were recognized were more conserved (i.e., with
lower Shannon Entropy) than those that were never recognized
(Figure S4; p,0.0001). Since Shannon Entropy is a measure of
HIV-1 variability for each segment of a protein alignment, it
assigns an identical entropy value for every 10-mer mapped to the
same segment of HIV, i.e., it does not discriminate all the specific
10-mer-variants that have the same HXB2 coordinates.
Thus, we chose an alternative way to evaluate the impact of
HIV-1diversity on ELISpot reactivity using a peptide-specific
metric. Based on 514 independent Nef HIV-1 subtype B
sequences, we calculated the population frequency of each
unique peptide derived from this dataset, i.e., the percentage of
sequences with the specific 10-mer. We found no relationship
between the population frequency of a 10-mer and CTL
targeting (Figure 6). There was no relationship between the
frequency of a 10-mer in the population and its frequency of
recognition among individuals: r
2=0.0599 (p,0.0001; Spear-
man’s correlation coefficient r was 0.2349, p,0.0001)
(Figure 6A). Likewise, there was no relationship between the
frequency of a 10-mer in the population and the magnitude of the
ELISpot responses: r
2=0.0256 (p=0.0027; Spearman’s correla-
tion coefficient r=0.1570, p=0.0032) (Figure 6B). These results
were confirmed when using a more recent and larger dataset of
1184 independent HIV-1 subtype B sequences (curated from
sequences available at the HIVDB in Dec. 2009) (data not
shown). Regarding the breadth of the CTL response, peptides
that were common in the population, i.e., consensus-like, were
recognized by an important proportion of our cohort – with up to
9 individuals recognizing the same peptide.
Cross-reactivity among CTL responses
It is particularly striking that peptides that were rare in the
population, i.e., found in less than 5% of circulating HIV-1
sequences, also elicited ELISpot responses in a number of
individuals. For example, a 10-mer found in 0.78% of circulating
sequences was recognized by 14 individuals (54% of our cohort).
There was a striking example of a peptide (PGIRYPITFG) found
in 0.39% of database sequences that was nonetheless recognized
by six individuals (average magnitude across the six individu-
als=250 SFC/M), while the consensus epitope was not recognized
(PGIRYPLTFG). To evaluate potential cross-reactivity between
variant peptides, we examined pairs of peptides in which one
peptide was found at least ten times more often among circulating
sequences than the other peptide. The idea is that, in such
situations, the reacting rare peptide is likely to be cross-reactive.
Figure 7 shows the fraction of epitopes that putatively cross-react
as a function of the number of AA differences between the two
epitopes. We found that epitopes with a single AA substitution
were likely to be recognized, and that recognition rates decreased
as the number of AA changes increased. Furthermore, we found
that the peptides are more likely to cross react if the AA changes
were conservative (p=0.03, 0.0044, 0.14 for 8, 9, and 10 mers,
respectively).
Figure 5. Magnitude of IFN-c ELISpot responses toward peptides that do or do not match each individual’s HIV-1 sequence. The
graph shows the magnitude of ELISpot responses as a function of the number of mutations between the peptide tested and the individual’s
autologous HIV-1 consensus sequence. This analysis was performed for the five individuals in our cohort from whom HIV-1 sequences were available.
doi:10.1371/journal.pone.0017969.g005
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Using a variation-encompassing library of 944 10-AA-long
peptides that recapitulated much of the diversity found among
circulating HIV-1 subtype B Nef peptides, we identified IFN-c
expressing responses against 350 peptides, including all but one of
the known optimal epitopes in Nef, and revealed many novel
epitope specificities after testing a set of only 26 HIV-1 infected
individuals. The peptide library consisted of consensus 10-mers
overlapping by 9 AA spanning the entire Nef protein and multiple
variants covering the range of Nef diversity found in HIV-1-B
infected individuals – with up to 8 peptidic variants for a consensus
10-mer. Our results suggest that variability-inclusive vaccine
antigens, such as mosaic or COT+, can expand the breadth and
depth of CTL responses, as shown recently in macaques [15,16].
We demonstrated recognition of 297 Nef peptides in addition to
the 53 (optimally-defined or not) epitopes that had previously been
recorded in the HIVDB – underlining that our understanding of the
determinantsof epitope recognition is fairly limited. It is particularly
significant that this is found for the oft-targeted Nef protein,
suggesting that our knowledge of epitopes in more variable proteins
such as Env is probably even more limited, as previously indicated
[21]. The 26 individuals in this cohort targeted a median of 7
discrete epitopic regions in Nef (up to 32 for one individual),
illustrating the common targeting of Nef peptides in chronically-
infected individuals as previously reported [17]. The cross-sectional
nature of our cohort and the availability of HIV-1 sequence data for
only five individuals did not allow us to make inferences on the
biological effectiveness of the responses we observed; indeed, we did
not see any relationship between the viral loads of the individuals
and the number of CTL responses they mounted or their
magnitude. So far, CTL responses to Nef have not been associated
with control of viral replication [11], rather they have been
associated to higher viralloads compared to responses to Gag which
have been associated to lower viremia [10,11].
Overall, reactive peptides weremore likely to correspondto more
conserved portions of the HIV-1-B Nef protein - the 350 peptides
that elicited ELISpot responses corresponded to viral regions of
significantly lower Shannon entropy than the HIV-1 regions
encompassing the 594 peptides that were not recognized
(p,0.0001). Although many CTL responses were detected towards
segments of lower Shannon entropy, highly variable segments were
also immunodominant targets – in such cases only certain variants
of a 10-AA-long viral segment could be recognized. Therefore, we
used a measure of diversity that was specific for each 10-mer variant
corresponding to the frequency of occurrence of each peptide
among circulating HIV-1-B sequences based on a dataset of 514
recorded Nef sequences obtained from HIV-1-B infected individ-
uals (using only independent sequences). We found no relationship
between the frequency of a peptide and either the frequency of
recognition in our cohort or the magnitude of the responses elicited.
We found that using a variability-enhanced peptide set
increased the breadth and depth of CTL responses, suggesting
that variability-inclusive vaccine strategies could elicit broader
recognition of epitopes. Indeed, use of mosaic antigens was
recently shown to enhance cellular immune responses in
vaccinated monkeys [15,16]. In variability-enhanced antigens,
inclusion of common variants is favored and rare peptides are
specifically excluded from the vaccine insert since these approach-
es were developed to compress HIV-1 variability in a vaccine
insert of practical size (e.g., 2 to 4 gene lengths). The hypothesis is
that common variants would be more likely to be found in
infecting strains. We tested the recognition of all the peptides that
would be included in 3 vaccine inserts and found that maximizing
coverage in the vaccine insert using the COT+ method was useful
to increase the number of peptides recognized. However, the
Figure 6. Population frequency of HIV-1-B Nef peptides and IFN-c ELISpot responses. The frequency of each unique 10-mer in a dataset of
514 independent Nef HIV-1 subtype B sequences is shown. Peptide reactivity data generated by IFN-c ELISpot assays done on 26 HIV-1 infected
individuals were used to analyze the relationship between the population frequency of a peptide and either its frequency of recognition in the cohort
(7A – left panel) or the magnitude of the IFN-c ELISpot responses c ELISpot response it elicited (7B – right panel).
doi:10.1371/journal.pone.0017969.g006
Figure 7. Cross-reactivity among HIV-1-B Nef peptides. The
fraction of peptides that cross-react is represented as a function of the
number of AA differences between the two peptides. For a pair of
peptides (with the same HXB2 coordinates), the fraction of peptides
that cross-react corresponds to the number of individuals who
recognized both peptides divided by the number of individuals who
recognized the more common one.
doi:10.1371/journal.pone.0017969.g007
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linear increase in recognition of epitopes due to increased-
coverage of the viral diversity found among circulating HIV-1-B
sequences. While a consensus peptide was generally the most likely
to be recognized, unique or very rare peptides were also
recognized. Of the 203 10-mer segments spanning Nef, 91 were
recognized using consensus peptides and 46 additional segments
were recognized using variants only (i.e., when the consensus was
negative). We observed diminishing returns in epitope recognition
as additional levels of variation (stratified by their population
frequency) were tested. Interestingly, in the recent mosaic vaccine
studies in monkeys, Santra et al. [16], using quadrivalent antigens,
reported a weaker enhancement of T cell responses than did
Barouch et al. [15] (using bivalent antigens). This difference may
be associated in part with a decreasing effectiveness with a
quadrivalent antigen compared to a bivalent one.
Unique viral peptides correspond to private mutations and
represent a significant and growing proportion of the peptides
found among circulating sequences, due to the extensive and
continuously expanding diversity of HIV-1. We found that 61
peptides found in less than 1% of circulating sequences were
recognized by at least one individual in our cohort, and 26 of these
rare peptides were recognized by three or more individuals (and
up to 14 individuals). For example, the consensus epitope
(PGIRYPLTFG) was not recognized while its variant PGIRY-
PITFG (found in 0.39% of database sequences) was recognized by
six individuals. In this instance, it might be preferable to switch the
consensus peptide for the L7I variant in a vaccine insert or peptide
set in order to augment epitope recognition. On an individual
basis, it was striking that most single mutations led to only modest
and non-significant decreases in the amplitude of the T cell
response. We showed that ELISpot responses elicited by these
unique/rare peptides may have been due to cross-recognition with
common variants: variants one AA away from the consensus
peptides were the most likely to react, and this was particularly
true if the AA substitution was conservative. Our data indicates
that epitope binding to T cell receptors is promiscuous and
conforms to the model proposed by McKinney and colleagues
[22], which demonstrated that multiple AA changes engineered in
epitopes still permitted CTL recognition in the context HLA-
A*0201 and HLA-A*1101. The breadth of recognition of peptide
variants is likely due in part to the promiscuity in TCR binding
[23]; our results showed no significant difference in the magnitude
of responses between variants, yet we could not draw conclusions
as to whether the functional profiles of the responses differed.
It remains to be understood what role is played by cross-
recognition of peptides in the control of viral replication. Knowing
HIV-1’s propensity to mutate, it is likely that several variants are
generated under CTL pressure and a number of cross-reactive
responses may be remainders of immune responses against initial
or previous viral variants – it is crucial to determine under which
conditions those variants cross-react and whether this has an
impact on the efficacy of the anti-viral CTL response. If a
multiplicity of peptides still induced substantial CTL responses
without significantly compromising viral fitness, there may be a
high genetic barrier to abolish CTL recognition. Hence protection
by such an epitope might be explained by the complex patterns of
mutations that are necessary for efficient escape.
Whether cross-reactivity has an effect on the CTL’s ability to
control viral replication is an open question that has important
implications for vaccine design. If cross-reactivity can broaden the
CTLresponseelicited bya vaccine and alsohasa positiveimpacton
the control of viremia, intrinsic cross-reactive specificities of HIV-1
should be harnessed to develop a potentially more immunogenic
vaccine candidate as a meansto confer broadly protective immunity
against multiple strains. However, the lack of association between
thepopulationfrequencyofanHIV-1peptideanditsrecognitionby
individuals in the cohort reported here also suggests that an
unrealistically large vaccine antigen size may be required to protect
against the universe of viral strains capable of establishing an
infection. In addition, since a number of responses were due to
cross-reactivity between rare and frequent peptides, we surmised
that a numberofthesevery rare peptides,whichareunlikely tohave
beenfound in the virusesfrom our infected subjects, may not induce
efficacious anti-viral responses, but rather represent decoy respons-
es. These results led us to discard our variability-inclusive COT+
vaccine strategy [13] in favor of a ‘Conserved Elements’ (CE)
vaccine design[24].CEvaccinesseek tofocusresponses onthe most
conserved segments of HIV-1 in order both to elicit CTL responses
considered obligatory for viral control and to avoid CTL responses
toward variant peptides that allow escape without hindering viral
function and that may act as immunological decoys with no clear
efficacy in terms of viral control.
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Figure S1 Frequency of 3,831 10-mer peptides in a Nef
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Figure S3 Magnitude of IFN-c ELISpot responses
toward consensus and variant peptides.
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Figure S4 HIV-1-B Nef variability and IFN-c ELISpot
recognition. Average Shannon Entropy scores were calculated
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from HIV-1 subtype B. Peptide-specific Shannon Entropy values
were compared based on their recognition in IFN-c ELISpot
assays done on 26 HIV-1 infected individuals.
(TIFF)
Table S1 IFN-c ELISpot responses detected against 944
Nef peptides (10-mer) in 26 HIV-infected individuals.
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